Bevacizumab in metastatic colorectal cancer and other settings Journal Article

  


Authors: Stenger, M.; Lichtman, S. M.
Article Title: Bevacizumab in metastatic colorectal cancer and other settings
Abstract: A landmark study in the treatment of colon cancer is the first to document the clinical benefit of antiangiogenic therapy. Bevacizumab has also shown promising activity in studies of non-small cell lung cancer and renal cell carcinoma, but the benefits and toxicities need to be explored further.
Keywords: vasculotropin; controlled study; survival rate; major clinical study; clinical trial; review; bevacizumab; fluorouracil; placebo; advanced cancer; diarrhea; drug withdrawal; hypertension; risk benefit analysis; paclitaxel; drug megadose; antineoplastic agent; colorectal cancer; carboplatin; low drug dose; metastasis; controlled clinical trial; phase 2 clinical trial; bleeding; leukopenia; lung non small cell cancer; randomized controlled trial; deep vein thrombosis; kidney carcinoma; irinotecan; lung embolism; survival time; death; systematic review; folinic acid; thrombosis; cancer relapse; phase 3 clinical trial; heterozygosity loss; kaplan meier method; von hippel lindau disease; oxaliplatin; digestive system perforation; antiangiogenic activity; proteinuria; meta analysis; recombinant alpha2b interferon; human
Journal Title: Community Oncology
Volume: 1
Issue: 4
ISSN: 1548-5315
Publisher: Elsevier Inc.  
Date Published: 2004-11-01
Start Page: 205
End Page: 208
Language: English
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-13844266155&partnerID=40&md5=43d6d5c61e84165478ad98d4ce5ddb41
Notes: Community Oncol. -- Export Date: 16 June 2014 -- Source: Scopus